Introduction {#sec1-1}
============

Pregnancy associated breast cancer (PABC) is a relatively rare clinical presentation. It's defined as breast cancer diagnosed during pregnancy or one-year following delivery (Psyrri, 2005). In developed countries he incidence of PABC during pregnancies is estimated between 1/10,000 to 1/3,000 . In previous studies, the rate of PABC in women younger than 45 years of age varied from 2.6% to 7% (Andersson et al., 2015; Vinatier et al., 2009). The incidence is currently increasing as more women are delaying their childbearing in industrialized nations (Andersson et al., 2015). In a large cohort population study of more than sixteen thousand patients aged between 15 to 44 years of age, PABC represents 7% (1,161 cases) of all breast cancers in this cohort, which doubled in incidence, from 16.0 to 37.4/100,000 childbirths during the study period (1963 to 2002) (Andersson et al., 2009). In this population, 30.1% of PABC patients were young between the ages of 25 and 29 year (Andersson et al., 2009).

The prognosis of PABC has been discussed in multiple studies with inconsistent results (Stensheim et al., 2009; Halaska et al., 2009). Amant et al., (2013) conducted an international collaborative study, a total of 311 PABC were eligible for analysis and they found there was no significant difference in both disease free survival and overall survival. While, in a met-analysis of 30 studies looking at PABC found that it was associated with poorer prognosis especially if diagnosed immediately post-partum (Azim et al., 2012). Breast cancer is an important health problem in Saudi Arabia. It ranks first among all newly diagnosed malignant diseases in Saudi Arabia and among women, accounting for 29.1% in the year 2013. It was reported that the incidence of breast cancer in patients less than 44 years of age was reported as 48.8% (Alghamdi et al., 2013). In Saudi Arabia, the average pregnancy rate is high, and women are likely to develop breast cancer at a younger age, it is plausible that a high frequency of PABC is to be expected (Ibrahim et al., 2000) Hence, association of pregnancy with Breast cancer frequently imposes serious management implications.

In this paper we aim to compare patients with PABC with a similar cohort of non PABC Patients, taking into regard the year of diagnosis for their outcomes.

Materials and Methods {#sec1-2}
=====================

This is a retrospective cohort review. The study was conducted in King Faisal Specialist hospital and Research Centre, Riyadh, Saudi Arabia; institutional review board (IRB) approval was obtained prior to starting the project. The patient's files and the breast cancer registry between the years 2001 to 2010 were reviewed and a total of 224 eligible individuals were identified. The study was conducted in a tertiary care hospital in Riyadh, Saudi Arabia from January to Decamber 2014. Pregnancy associated breast cancer (PABC) was defined in the inclusion criteria as patients diagnosed with breast cancer while pregnant. A total of 110 female PABC was identified and a further, 114 female non-pregnant breast cancer patients diagnosed in the same time frame during the period of 2001 to 2010 were identified and included as a comparison.

Stage 1 and 2 patients were classified as Early Stage, Stage 3 and 4 patients were classified as Advanced Stage patients. Her-2 was considered positive if it was +3 or if it was +2 and the FISH amplified. Statistical analysis is intended to test the hypothesis that pregnant breast cancer women have different outcomes in comparison to the non-pregnant breast cancer women. Statistical analysis was conducted using SAS 9.3 and R-2.14.1. Overall Survival (OS) probabilities have been calculated using Kaplan-Meier method. Log-Rank test has been used to compare the difference between the survival probabilities. Cox regression model was used to obtain difference in hazard rates between two groups.

Results {#sec1-3}
=======

A total of 110 patients in PABC group 1 and 114 patients in non-pregnant group were identified during the study period. In PABC, the median age was 34 years (20 -- 45 years) whereas in non-pregnant group was 44 years (24 to 48 years), all the patients were diagnosed at the same time interval. The median follow up was 34 months in PABC group and 54 months in non-pregnant group. PABC consisted of more triple negative disease (23%) compared to15% non-pregnant group and this was found to be statistically different (P value=0.05). In the PABC group 55.7% presented at an advanced stage while only 36.7% of the non-pregnant group presented late, this was also statistically significant (P value= 0.01%) ([Table 1](#T1){ref-type="table"}). Her-2 positive and negative patients were fairly the same in both groups. In pregnant patients, 33 patients have been died while 84 patients were alive.The 5-year survival rate was 65% . However, in non-pregnant patients, 20 have been denied while 100 were censored. The survivial propability was 82%, (P value=0.002) ([Figure 1](#F1){ref-type="fig"}). Disease free survival (DFS) was 47.5% vs 65.4% (P value =0.002). ([Figure 2](#F2){ref-type="fig"}). thirty-three patients have been relapsed or died in remission, while 75 patients were censored.

###### 

Baseline Characteristics and Outcomes

  Median Age years            Pregnant        Not-Pregnant   P-value                                   
  --------------------------- --------------- -------------- --------- --------------- -------- ------ -------
   ER+/PR+                    43              35.80%                   58              48.70%          0.2
   ER+/PR-                    8               6.70%                    10              8.40%           
   ER-/PR+                    7               5.80%                    5               4.20%           
   ER-/PR-                    57              47.50%                   43              36%             
   Un Known                   5               4.00%                    3               3%              
   Triple negative            29              24.00%                   17              14%             0.05
   non-triple -ve             93              76.00%                   103             85.80%          
   Early Stage                42              34.00%                   59              49%             0.01
   Advanced-stage             68              55.70%                   44              36.70%          
   Not Known                  12              10.00%                   17              14%             
                                                                                                       
  Median follow-up (months)   34 (1 to 132)                            54 (3 to 162)                   
                                                                                                       
   Her 2 --ve status          63              60.6%                    57              61%             0.5
   Her2 +ve status            41              39.40%                   36              38.70%          
   OS                         117             68.90%         0.05      120             81%      0.04   0.006
   DFS                        117             50.80%         0.05      120             64%      0.05   0.01

![Kaplan-Meier Curve of the Cumulative Survival and Overall Survival in Months. The *P-value* is derived from log rank test for overall comparison of overall survival.](APJCP-20-135-g001){#F1}

![Kaplan-Meier Curve of the Cumulative Survival and Disease Free Survival in Months. The *P-value* is derived from log rank test for overall comparison of disease free](APJCP-20-135-g002){#F2}

Discussion {#sec1-4}
==========

In this retrospective review study amongst women of childbearing age, we observed that the median age of PABC patients was more trending towards younger age from their matched controls, even in selected young population. Furthermore, they were diagnosed at a more advanced stage and had a poorer immuno-histological prognostic profile, with more tumors being negative for hormonal receptors, both ER and PR and Her 2/neu negative. Our results showed that patients presented with advance stage with PABCs and this is described frequently in PABC (Beadle et al., 2009; Stensheim et al., 2009; Rodriguez et al., 2008). Furthermore, according to Genin et al. in comparison with the non-PABCs, PABC group has a greater HER2 expression and hormone receptor (ER, PR) negative status which adds to their unfavorable prognosis and were more likely to present with T3 or T4 tumors (Genin et al., 2012). Some mechanisms may potentially explain the association between pregnancy and a worse outcome. The changes that occur in the breast during pregnancy is well-known, one study compared surgical specimens of PABC patients and non-pregnant controls and it was seen that there was a significant increase in angiogenesis in tumor tissues and healthy breast tissue in the PABC when compared with the non-pregnant controls, however, there was no difference seen in lymphangiogeneis (Genin et al., 2014). Most PABCs do not express hormone receptors, one theory studied observed that high levels of circulation estrogen promoted the formation of ER-negative cancers and it also increased systemic angiogenesis, stromalization and bone marrow cell recruitment (Gupta et al., 2007).

Our results are also similar with other studies that showed PABC was associated with poor prognosis, shorter 5-year survival rate and DFS against its matched controls. Maggard et al looked at specifically outcomes of young patients with breast cancer reviewed 4,616 young females using the Surveillance, Epidemiology, and End Results cancer database described that young patients had worse 5 year survival and tended to present with advanced stage of disease and have more estrogen and progesterone negative tumors (Maggard et al., 2003). A recent met-analysis of 41 studies that looked that prognosis of PABC found that breast cancer diagnosed during pregnancy was more likely to result in death and decreased disease free survival (Hartman, 2016 ).

In Saudi Arabia, it was reported in the Cancer registry that 42% were diagnosed with lymph node spread (regional) and 13% had distant metastasis at the time of diagnosis and these stages have a lower survival advantage than early stage breast cancer. Earlier studies conducted in different regions of Saudi Arabia such as Buraidah, Riyadh, and Al Khobar, have explored female knowledge, and the attitude towards breast cancer, which revealed lack of knowledge about the risk factors for breast cancer; and lack of understanding of the importance of self-breast examination and screening mammography (Alam, 2006; Dandash and Al-Mohaimeed, 2007; Amin et al., 2009 ). These factors hinder the diagnosis of breast cancer at an early stage in both pregnant patients and non-pregnant patients. Other, factors in pregnancy and breast feeding that can further delay diagnosis is that increase in the breast density makes clinical examinations and breast imaging more difficult to interpret.

According to Azim et al., (2012) met analysis, the prognosis of breast cancer arising during pregnancy was significantly associated with poor overall survival, based on the pooled analyses of the univariate and multivariate models. Another case matched control study that matched patients for age, year of surgery, stage and neoadjuvant chemotherapy found that there was no difference in tumor characteristics between the two groups; however, they found that PABC had significantly poorer DFS and a trend of a worse OS.

In conclusion, patients diagnosed with PABC are independently associated with more advanced stage, poor immune-histochemistry leading to poor survival. PABC should be recognized as a special category of breast cancer that is associated with poor outcomes. The majority of the population in Saudi Arabia and most developing countries are younger and breast cancer is frequently diagnosed in these childbearing years. This leads us to suggest that awareness programs for both the population and the healthcare professional about PABC would lead to early detection and prompt management thereby leading to better outcomes. Furthermore, research of the tumor biology beyond phenotyping is warranted as this will lead to better understanding of PABC and guide treatment.
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